Phase 2 Tuberculosis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People diagnosed with a type of tuberculosis (TB) that responds to the standard TB medicines rifampicin and isoniazid, confirmed by a sputum (mucus) test, AND who are either newly diagnosed with TB or have not received any TB treatment for at least 3 years after being cured of a previous TB episode
- People who are not able to become pregnant, or who are using reliable contraception (birth control)
- People who weigh at least 35 kilograms
Who may not be able to join:
- People whose general health and ability to carry out daily activities falls below a certain level, as measured by a standard health scoring tool called the Karnofsky scale (confirm with trial site)
- People who have TB that has spread outside the lungs to other parts of the body
- People with certain heart conditions or other factors that increase the risk of a specific heart rhythm problem (confirm with trial site)
- People who are pregnant or currently breastfeeding
- People whose blood test results fall outside acceptable ranges as set out in the trial's guidelines (confirm with trial site)
- People living with HIV who have a very low level of immune cells (CD4+ count below 200 cells per microlitre), indicating a severely weakened immune system
- People living with HIV who have a severe stage of HIV disease (classified as WHO Clinical Stage 4)
- People living with HIV who do not agree to take a specific combination of HIV medicines (DTG/TFV/3TC) during the study, if HIV treatment is needed
- People living with HIV who are known to have had a bad reaction to, not responded to, or have a medical reason preventing them from taking the HIV medicine combination DTG/TFV/3TC, if HIV treatment is needed
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Morounfolu Olugbosi, TB Alliance
Phone: +27 83 30 76784
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence and characterization of treatment-emergent adverse events (TEAEs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.